PV-Complete-Pipeline as a Microfluidic Chip

March 2026 | Cross-Domain Transfer | 8 min read

The 15-step pv-complete-pipeline — the microgram chain that routes a drug-event pair from raw signal through causality assessment to regulatory action — maps directly onto a 25mm x 40mm PDMS microfluidic chip. Each microgram decision gate becomes a physical Y-junction. Each chain step becomes a channel. The molecule either passes the safety boundary or gets diverted to a waste well. The transfer is not metaphorical: the same primitive structure (comparison, sequence, persistence, location, irreversibility) operates in both substrates.

Design principle: Algorithm 3 (TRANSFER) — same primitive structure, different boundary (digital to physical).

Fabrication target: PDMS soft lithography or resin micro-3D print (Formlabs/Nanoscribe).

The 15-step pipeline maps to a 25mm x 40mm microfluidic chip with 4 phases flowing top-to-bottom. Sample enters through an inlet port at the top left, traverses validation, bridging, assessment, and enrichment phases, and exits through one of five output wells. Only one well — PERSIST — represents a confirmed, causally assessed, committed signal worth monitoring. The other four are diversion points where insufficient evidence terminates the analysis.

Phase 1: VALIDATE (Blue Channels)

Sample enters through the inlet port. Four reaction chambers in series, each containing a different assay reagent.

COMBINER — A multiplex immunoassay chamber. The drug metabolite reacts with four antibody conjugates (PRR/ROR/IC/EBGM equivalents). Each produces a fluorescent signal proportional to disproportionality. This is the physical analog of the signal-combiner microgram that runs all four disproportionality measures in parallel.

VALIDATE — An optical detection zone. A photodiode reads fluorescence intensity. If the signal falls below the threshold, a Y-junction diverts the sample to the NO_SIGNAL waste well. This is the first decision gate — the chip equivalent of the signal-validate microgram checking whether any measure exceeds its threshold.

TREND — A serpentine delay channel plus a second measurement point. The serpentine geometry creates a time delay, allowing two concentration measurements at different points along the flow path. Comparing these yields a delta direction — is the signal increasing or decreasing? The physical implementation of temporal trend analysis.

RECUR — A pattern matching chamber via molecular imprinting. The chamber contains polymer imprinted with known ADR metabolite signatures. If the sample matches a known recurrence pattern, binding occurs and signal amplifies. If not, the sample passes through unmodified.

Phase 2: BRIDGE (Orange Channel)

A mixing chamber where validation reagents combine with assessment reagents. The concentration of validation products (a confidence proxy) determines the mixing ratio — high confidence means more assessment reagent flows. This is the physical bridge between "is there a signal?" and "what does it mean?" — the same function as the signal-to-causality microgram that translates statistical output into causality input.

Phase 3: ASSESS (Green Channels, Right-to-Left Flow)

The core diagnostic battery. Flow reverses direction here, running right-to-left across the chip.

PRR — A threshold detection chamber. A competitive binding assay where the drug-event complex competes with a reference standard. Signal above threshold means the drug-event pair is reported at a rate that exceeds background. Below threshold, the sample diverts to the NOISE waste well. This is the second decision gate.

SIG-to-CAUS — An enzymatic cascade chamber. The metabolite triggers an enzyme cascade only if the reaction is mechanistically consistent. This bridges statistical signal (the PRR result) to biological plausibility — the physical equivalent of checking whether a pathway exists between drug mechanism and observed event.

NARANJO — A 10-compartment scoring chamber. Each compartment tests one Naranjo criterion via a specific binding assay. Positive compartments produce a marker dye. The number of colored compartments is the physical Naranjo score. Ten chambers, ten questions, same algorithm — but the "answers" come from molecular interactions instead of clinical chart review.

ACTION — A fluidic logic gate. The number of Naranjo markers determines which output channel activates: high score routes to the expedite channel, low score routes to the monitor channel. This is the causality-to-action microgram — the decision that converts assessment into operational response.

Phase 4: ENRICH (Purple Channels)

Six parallel/series measurement chambers implementing the enrichment algorithms.

ENERGY — A calorimetric chamber that measures heat generated by downstream reactions. Literally measuring the energy of state change — the physical analog of counting directed changes in signal state.

CONVERGE — A recirculation loop. The sample passes through a detection zone multiple times. Each pass refines the measurement. When the delta between consecutive passes drops below a tolerance threshold, the measurement has converged. The loop stops. This is iterative refinement made physical.

VOID — A 7-well plate. Each well tests for the presence or absence of one required data element. Empty wells are voids — missing data. The number of filled wells tells you how complete the evidence is. A physical implementation of data completeness scoring.

LOCATE — A gradient channel. The sample migrates through a concentration gradient, binding at specific locations based on its molecular properties. Where it binds identifies its mechanism class. This is spatial classification — the chip places the signal in a taxonomy based on physical behavior rather than lookup tables.

SEAL — An irreversible binding chamber. The final assessment is committed via covalent crosslinking. Once sealed, the verdict cannot be reversed. This is actual irreversibility — the physical primitive that makes a finding permanent. If the sample fails to bind (insufficient evidence for covalent commitment), it diverts to the BLOCK waste well. This is the third decision gate.

SELECT — A frequency-gated output. A piezoelectric valve opens only if the cumulative signal exceeds a threshold. Samples that pass go to the PERSIST well. Those that fall short go to the DECAY well. This is the final gate — the fourth decision point that determines whether the signal is worth sustained monitoring.

Output Wells

A sample that reaches PERSIST has survived four decision gates, been scored on ten causality criteria, passed through six enrichment algorithms, and been covalently sealed. In the digital pipeline, this takes 7.5 seconds of computation. On the chip, it takes 7.5 minutes of fluid flow.

The schematic renders a 28 x 18 inch dark-field layout with the four phases arranged top-to-bottom. Phase 1 (VALIDATE) occupies the top row in blue: sample inlet at far left, four chambers (COMBINER, VALIDATE, TREND, RECUR) connected in series by 200-micron channels, with a Y-junction after VALIDATE that diverts to the NO_SIGNAL waste well below. Phase 2 (BRIDGE) is a single orange chamber at the right edge, connected by a vertical channel dropping from Phase 1 to Phase 3. Phase 3 (ASSESS) runs right-to-left across the middle row in green: PRR, SIG-to-CAUS, NARANJO, and ACTION chambers, with a Y-junction after PRR diverting to the NOISE waste well. Phase 4 (ENRICH) spans the bottom row in purple: ENERGY, CONVERGE, VOID, LOCATE, SEAL, and SELECT chambers in series, with the SEAL junction diverting to BLOCK and the final SELECT junction splitting to PERSIST (green well) or DECAY (red well). Four reagent inlets line the top-right edge for PRR, Naranjo, causality, and wash buffer. A gold border frames the entire chip at 25mm x 40mm.

1. Design — Export channel layout as SVG/DXF for photomask.
2. Mold — Spin-coat SU-8 on silicon wafer, UV expose through mask, develop.
3. Cast — Pour PDMS over mold, cure at 65 degrees C for 2 hours.
4. Bond — Oxygen plasma treatment, bond PDMS to glass slide.
5. Connect — Insert tubing into inlet/outlet ports.
6. Load — Fill chambers with assay reagents.
7. Test — Run known drug sample, verify output well matches expected verdict.

The second code cell generates a fabrication-ready SVG photomask at 40mm x 25mm (standard microscope slide compatible). The mask follows photolithography conventions: black regions block UV light and define where channels will be etched into SU-8 photoresist; white regions allow UV through and become the solid PDMS walls.

The mask encodes the full chip topology: 5 inlet ports along the top edge (1 sample, 4 reagent), 15 rectangular reaction chambers distributed across the four phases, 4 Y-junction decision gates rendered as triangular features, 5 circular collection wells (1 PERSIST, 4 waste), and all connecting channel paths at 2 SVG-unit width (representing 200 microns at 1:1 print scale).

To fabricate from the mask:

1. Print SVG at 1:1 scale on transparency film (25,400 dpi recommended).
2. Use as contact photomask for SU-8 photolithography on silicon wafer.
3. Develop SU-8 to create raised channel features.
4. Cast PDMS over the developed SU-8 mold.
5. Bond to glass slide with oxygen plasma.
6. Connect tubing to the 5 inlet ports.
7. Load reagents and run sample.

The fact that a digital decision pipeline can be mapped onto a physical microfluidic chip without losing structural fidelity is not an engineering curiosity. It demonstrates that the primitives underlying the PV pipeline — comparison, sequence, persistence, location, irreversibility — are substrate-independent. They are not properties of software. They are properties of the assessment logic itself.

A Y-junction on a chip performs the same function as a condition node in YAML: it routes flow based on a threshold. A serpentine delay channel performs the same function as a trend calculation: it creates temporal separation for comparison. Covalent crosslinking performs the same function as a SEAL verdict: it makes a finding irreversible.

The pipeline does not merely describe what to compute. It describes a topology — and topologies transfer across substrates.